.Pharmacolibrary.Drugs.S_SensoryOrgans.S01C_AntiinflammatoryAgentsAndAntiinfectivesInCombina.S01CA08_MethylprednisoloneAndAnt.MethylprednisoloneAndAnt .Pharmacolibrary.Drugs.S_SensoryOrgans.S01C_AntiinflammatoryAgentsAndAntiinfectivesInCombina.S01CA08_MethylprednisoloneAndAnt.MethylprednisoloneAndAnt| name: | MethylprednisoloneAndAntiinfectives |
| ATC code: | S01CA08 | route: |
| n-compartments | 0 |
Methylprednisolone and antiinfectives (ATC S01CA08) is a combination ocular drug preparation intended for the treatment of eye infections and inflammation. Methylprednisolone is a corticosteroid used for its anti-inflammatory and immunosuppressive properties, while the antiinfective component prevents or treats bacterial infections. This combination is primarily used in ophthalmology to manage inflammatory eye conditions with a concurrent risk or presence of infection. Not all countries have this specific combination approved, and its availability may vary.
No pharmacokinetic studies or published PK models specific to the combined preparation of methylprednisolone and antiinfectives (S01CA08) for ophthalmic use were identified in the literature. Thus, PK parameter values are not directly available.
Suetsugu, K, et al., & Ieiri, I (2021). Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study. Drugs in R&D 21(4) 419–429. DOI:10.1007/s40268-021-00365-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34655050
Wu, Y, et al., & Liu, T (2025). Drug-drug interaction of phenytoin sodium and methylprednisolone on voriconazole: a population pharmacokinetic model in children with thalassemia undergoing allogeneic hematopoietic stem cell transplantation. European journal of clinical pharmacology 81(3) 365–374. DOI:10.1007/s00228-024-03795-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39714727
Hodel, K, et al., & Godoy, AL (2024). Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects. Current pharmaceutical biotechnology 25(13) 1651–1663. DOI:10.2174/0113892010264503231108070917 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38258769